Procyrion Welcomes New Leadership: Jason Whiting as CEO
Procyrion, Inc., a trailblazer in medical devices, has announced a significant leadership transition with the appointment of
Jason Whiting as the new
Chief Executive Officer. This strategic move comes as the former CEO, Dr.
Eric S. Fain, prepares to retire after more than eight successful years at the helm. Under Dr. Fain’s direction, Procyrion has made tremendous strides in developing the
Aortix® system, a pioneering solution designed to improve the care of patients grappling with cardiac and renal issues.
Dr. Fain will continue to play a vital role in the company's future, remaining on the
Board of Directors, where he will lend support during this transitional phase that aims to propel Procyrion from clinical development towards commercialization.
The Aortix device, currently under clinical trials, is aimed at patients dealing with
acute decompensated heart failure (ADHF), particularly those facing the challenges of
cardiorenal syndrome (CRS). The pivotal
DRAIN-HF trial, which is accumulating participants, seeks to address the unfortunate plight of individuals whose condition persists despite conventional treatments, often leaving them with limited options. Additionally, this trial includes a registry function to cater to those with end-stage heart failure, many of whom are at a high risk of requiring advanced interventions like a left ventricular assist device (LVAD) or a heart transplant.
Gary Burbach, chairman of the board, expressed his gratitude towards Dr. Fain. He noted, “On behalf of the Board, I want to thank Eric for more than eight years of exceptional leadership. His strategic vision has transformed the Aortix project from a prototype into a robust design eligible for designation as a
Breakthrough Therapy during its pivotal trial.”
The board aims to establish a firm foundation during this transitional period, seeking a leader like Whiting who possesses substantial commercial experience vital for Procyrion’s progress into its next chapter.
Jason Whiting, accomplished with over 25 years in the medtech sector, comes primed for the challenge. His past roles, including recent CEO of
Avation Medical, have been marked by successful positioning of innovative technologies, which he hopes to replicate at Procyrion. His background encompasses a diverse range of experiences from wearable devices to implantable technologies, emphasizing therapies targeted at improving heart failure outcomes.
“I am honored to join Procyrion at such an imperative point in the company’s evolution,” said Whiting. “I look forward to building on the incredible work done by Eric and the team. The Aortix system is a uniquely differentiated catheter-based solution with the potential to significantly advance care for patients experiencing heart failure and kidney disorders.”
As CEO, Mr. Whiting aims to ensure the successful completion of patient enrollment in the
DRAIN-HF study while navigating regulatory pathways to secure market access. Aiming to establish a comprehensive foundation for therapy adoption and commercialization is equally vital to his strategy. The overarching mission will remain a focus on delivering impactful treatments for patients facing significant medical challenges.
About Procyrion
Procyrion, Inc. is a privately held medical device company focused on enhancing treatment options for individuals with
cardiac and renal impairments. They are currently innovating the
Aortix® system, a cutting-edge percutaneous mechanical circulatory support device. Notably, Aortix is still under investigational use and not yet approved for marketing in any region. For more details, visit
Procyrion’s website.
This leadership change signals a pivotal moment for Procyrion as it positions itself to deliver revolutionary options for patients who require immediate and effective interventions against heart failure and related conditions.